Related Experiment Video
Updated: Jan 13, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
Real-World Evidence on Mobile App-Supported Diabetes Management in Insulin-Treated Patients
Lena Roth1, Julian Stein1, Peter E H Schwarz1
1Department for Prevention and Care of Diabetes, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, tu-dresden.de.
Journal of Diabetes Research
|January 7, 2026
Summary
The mobile diabetes app ESYSTA significantly improved glycemic control, with HbA1c levels reducing by -0.59% after six months and sustained long-term. Real-world data show its effectiveness in managing diabetes.
Area of Science:
- Digital Health
- Diabetes Management
- Real-World Evidence
Background:
- Digital health interventions, like mobile diabetes apps, aim to improve glycemic control.
- Real-world data (RWD) offer insights into long-term effectiveness beyond clinical trials.
Purpose of the Study:
- To evaluate the effectiveness of the ESYSTA mobile diabetes app in enhancing glycemic control using RWD.
- Assess long-term HbA1c changes in users of the ESYSTA app.
Main Methods:
- Retrospective analysis of 475 ESYSTA users.
- Assessed HbA1c changes at 6, 12, and 15 months.
- Linear mixed-effects model used to adjust for confounding factors.
Main Results:
- Significant HbA1c reduction of -0.59% after 6 months, sustained up to 15 months.
- Greater HbA1c reduction observed in users with higher baseline HbA1c.
- 75% of users consistently tracked blood glucose throughout the study period.
Conclusions:
- Mobile diabetes apps, like ESYSTA, demonstrate effectiveness in improving long-term glycemic control.
- Real-world evidence supports the sustained benefits of digital health interventions for diabetes.
- Further controlled studies are needed to confirm findings and explore mechanisms.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
01:16Insulin: Dosing Regimen and Adverse Effects
673
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
673
01:22Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
01:22Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581